Zymeworks Appoints New Director
June 29, 2023 16:05 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 29, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Set to Join Russell 3000®, Russell 2000®, and Russell Microcap® Indexes
June 26, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 26, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Participation in Upcoming Investor Conferences
June 01, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, June 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today...
Zymeworks Announces Departure of Neil Klompas, President and Chief Operating Officer
May 18, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, May 18, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced...
Zymeworks Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 08, 2023 16:05 ET
|
Zymeworks Inc.
Confirmed prior guidance on 2023 operating cash burn of between $90 and $120 million and cash runway through at least 2026, and potentially beyondNet quarterly loss decreased by 66% to $24.4 million...
Zymeworks Announces Participation in Upcoming Investor Conferences
May 01, 2023 08:30 ET
|
Zymeworks Inc.
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing novel, multifunctional biotherapeutics, today announced...
Zymeworks Presents New Data from Multiple Preclinical and Clinical Development Programs at the 2023 American Association for Cancer Research Annual Meeting
April 18, 2023 16:05 ET
|
Zymeworks Inc.
● ZW191 demonstrates strong responses in FRα-low expressing patient-derived xenograft (PDX) models with favorable pharmacokinetic and safety profiles● ZW171 induced potent preferential killing of...